Gratwohl Alois, Niederwieser Dietger
Hematology, University Hospital Basel, Petersgraben 4, Basel, Switzerland.
Curr Probl Dermatol. 2012;43:81-90. doi: 10.1159/000335266. Epub 2012 Feb 17.
Hematopoietic stem cell transplantation (HSCT) has evolved over the last half century from experimental bone marrow transplantation for patients with incurable leukemia or bone marrow failure to standard of care for a broad range of patients with congenital or acquired disorders of the hematopoietic system or radio-, chemo- or immune-sensitive malignancies. More than 60,000 such transplants are currently carried out annually worldwide with increasing frequency. HSCT has always been closely linked to Dermatology from its very beginning through its main and most devastating complication graft-versus-host disease. Treatment complications of HSCT have provided a great deal of insight into basic mechanisms of immunology, clinical medicine and networking in general. It remains a challenge to turn this knowledge from the two disciplines into benefit for the future patients with disturbed immune function and skin diseases.
造血干细胞移植（HSCT）在过去半个世纪中已从针对无法治愈的白血病或骨髓衰竭患者的实验性骨髓移植，发展成为针对广泛的先天性或后天性造血系统疾病或对放疗、化疗或免疫敏感的恶性肿瘤患者的标准治疗方法。目前，全球每年进行超过60000例此类移植，且频率不断增加。从一开始，HSCT就因其主要且最具破坏性的并发症移植物抗宿主病而与皮肤病学紧密相连。HSCT的治疗并发症为免疫学、临床医学及一般网络的基本机制提供了大量深入见解。将这两个学科的知识转化为对未来免疫功能紊乱和皮肤病患者的益处，仍然是一项挑战。
